Department of Health Abu Dhabi (DoH), the regulator of healthcare in the emirate, has signed a Declaration of Collaboration with Johnson & Johnson Middle East FZ-LLC to support Abu Dhabi’s vision of developing a regional center for clinical research and data generation. In addition to bringing innovative treatments and breakthrough solutions to the UAE and the MENA region, the collaboration will also allow for the exchange of knowledge and experiences across the health sector.
The signing ceremony, witnessed by Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health Abu Dhabi (DoH), took place during BIO International Convention 2022, held between 13-16 June in San Diego, California. The Declaration of Collaboration was signed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, and Jamie Phares, Managing Director of Janssen GCC, one of Johnson and Johnson’s pharmaceutical companies.
The Abu Dhabi delegation will showcase the growth and development of Abu Dhabi’s biotechnology industry at BIO International Convention 2022. The collaborations will explore key potential areas of interest for developing short and long-term projects in the generation of Data and Real-World Evidence (RWE). In order to establish the strength and sustainability of the healthcare sector and to provide patient care of a high standard, Abu Dhabi seeks to lead research groups supported by global partners.
With a robust growth potential, Abu Dhabi’s biopharmaceutical and healthcare value chain continues to see collaboration opportunities emerge due to its strong infrastructure and advanced healthcare ecosystem. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as provide quality care to patients.